News
Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback